An Open Label, Dose-Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Pharmacokinetics of TAK-981 in Adult Patients With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies

Brief Summary

Type:
Lymphomas

Study Type:
Treatment

Phase:
I

ClinicalTrials.gov Identifier:
NCT03648372

Study #:
STUDY00144747

Start Date:
Dec 12, 2021

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03648372

View Complete Trial Details & Eligibility at ClinicalTrials.gov